Literature DB >> 11049982

A minimal c-fes cassette directs myeloid-specific expression in transgenic mice.

A Heydemann1, S Warming, C Clendenin, K Sigrist, J P Hjorth, M C Simon.   

Abstract

The c-fes proto-oncogene encodes a 92-kd protein tyrosine kinase whose expression is restricted largely to myeloid and endothelial cells in adult mammals. A 13.2-kilobase (kb) human c-fes genomic fragment was previously shown to contain cis-acting element(s) sufficient for a locus control function in bone marrow macrophages. Locus control regions (LCRs) confer transgene expression in mice that is integration site independent, copy number dependent, and similar to endogenous murine messenger RNA levels. To identify sequences required for this LCR, c-fes transgenes were analyzed in mice. Myeloid-cell-specific, deoxyribonuclease-I-hypersensitive sites localized to the 3' boundary of exon 1 and intron 3 are required to confer high-level transgene expression comparable to endogenous c-fes, independent of integration site. We define a minimal LCR element as DNA sequences (nucleotides +28 to +2523 relative to the transcription start site) located within intron 1 to intron 3 of the human locus. When this 2.5-kb DNA fragment was linked to a c-fes complementary DNA regulated by its own 446-base-pair promoter, integration-site-independent, copy-number-dependent transcription was observed in myeloid cells in transgenic mice. Furthermore, this 2.5-kb cassette directed expression of a heterologous gene (enhanced green fluorescent protein) exclusively in myeloid cells. The c-fes regulatory unit represents a novel reagent for targeting gene expression to macrophages and neutrophils in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049982

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Activated Fes protein tyrosine kinase induces terminal macrophage differentiation of myeloid progenitors (U937 cells) and activation of the transcription factor PU.1.

Authors:  Jynho Kim; Ricardo A Feldman
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

Review 2.  Locus control regions.

Authors:  Qiliang Li; Kenneth R Peterson; Xiangdong Fang; George Stamatoyannopoulos
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 3.  Macrophage-specific gene expression: current paradigms and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

4.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

5.  Thymic stromal lymphopoietin and the pathophysiology of atopic disease.

Authors:  Michael M Miazgowicz; Mark B Headley; Ryan P Larson; Steven F Ziegler
Journal:  Expert Rev Clin Immunol       Date:  2009-09-01       Impact factor: 4.473

6.  The use of human CD68 transcriptional regulatory sequences to direct high-level expression of class A scavenger receptor in macrophages in vitro and in vivo.

Authors:  P J Gough; S Gordon; D R Greaves
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

7.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Authors:  Christian Brendel; Walther Hänseler; Vital Wohlgensinger; Matteo Bianchi; Serap Tokmak; Linping Chen-Wichmann; Elena Kuzmenko; Nikola Cesarovic; Flora Nicholls; Janine Reichenbach; Reinhard Seger; Manuel Grez; Ulrich Siler
Journal:  Hum Gene Ther Methods       Date:  2013-05-02       Impact factor: 2.396

8.  FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to hematopoietic stem cells in the bone marrow.

Authors:  P Keller; J L Payne; G Tremml; P A Greer; M Gaboli; P P Pandolfi; M Bessler
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

Review 9.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.